HeidiCraytonMD

Neurology • Vienna, VA

Neuroimmunology/Multiple Sclerosis

Medical Director at MS Center of Greater Washington

Join to view full profile

Dr. Crayton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Crayton's full profile

Already have an account?

Office
8320 Old Courthouse Rd
Suite 400
Vienna, VA 22182
Phone+1 703-226-4000

Fax+1 703-226-4010

Education & Training

MedStar Health/Georgetown University HospitalResidency, Neurology, 1994 - 1997
Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1993 - 1994
MCP-Hahnemann College of MedicineClass of 1993

Certifications & Licensure

VA State Medical License 1997 - 2026
DC State Medical License 1997 - 2013
MD State Medical License 1997 - 1998
PA State Medical License 1993 - 1994
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
Completed
Phase 2
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01
Terminated
Phase 3

Publications & Presentations

PubMed

26 citations
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Rafael Arroyo González, Mariko Kita, Heidi Crayton, Eva Havrdova, David Margolin
Multiple Sclerosis. 2017-09-01
69 citations
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study...
Edward Fox, Keith R. Edwards, Gordon Burch, Daniel Wynn, Chris LaGanke
Multiple Sclerosis and Related Disorders. 2014-09-01
32 citations
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: ...
Jonathan Calkwood, Bruce A.C. Cree, Heidi Crayton, Daniel Kantor, Brian Steingo
BMC Neurology. 2014-11-26

Press Mentions

I Have MS and I’m Very LuckyMay 22nd, 2018

External Links

MS Center of Greater Washingtonhttp://www.drcrayton.com